Download the app
App StorePlay Store
Beige
Login
← All tags

dr reddys

Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27

Dr Reddy’s bets on semaglutide and abatacept to revive margins and momentum by FY27

Dr Reddy’s Laboratories expects a gradual recovery in the coming fiscal year after last year’s profit dip hit by pressures in the US business. Growth remains solid across India, Europe, and emerging markets. The company’s outlook leans on upcoming launches including semaglutide and abatacept, alongside improved product mix and tighter cost controls to lift margins by FY27.

Summarised by Beize from a story on The Economic Times on 14 May 2026
Dr Reddy’s Q4 profit plunges 86% YoY as revenue drops and dividend disappoints

Dr Reddy’s Q4 profit plunges 86% YoY as revenue drops and dividend disappoints

Dr Reddy’s Laboratories reported a sharp 86% year-on-year fall in consolidated net profit to Rs 221 crore for the March-ended quarter. Revenue also declined 12%, adding pressure to the business outlook. Despite the steep profit drop, the company announced a dividend of Rs 8 per share, offering a small positive for investors.

Summarised by Beize from a story on The Economic Times on 12 May 2026

Your news, in seconds

App StorePlay Store
Dr Reddy’s and Nestle launch Celevida GLP+ for diabetes and obesity patients

Dr Reddy’s and Nestle launch Celevida GLP+ for diabetes and obesity patients

Dr Reddy’s has joined forces with Nestle Health Science to roll out Celevida GLP+, a nutrition supplement designed for people managing type 2 diabetes and obesity while on GLP-1/GIP therapy. The collaboration aims to address day to day nutritional challenges that can emerge during treatment, adding a targeted option beyond standard diabetes and weight management care.

Summarised by Beize from a story on The Economic Times on 7 May 2026
Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s wins Health Canada approval for generic semaglutide injection first in Canada

Dr Reddy’s Laboratories has received market authorization from Health Canada for its generic semaglutide injection, becoming the first company approved for the diabetes therapy in Canada. The Bengaluru-based pharma is now preparing a launch to expand access for patients who rely on the treatment, potentially easing pressure on medication availability and costs.

Summarised by Beize from a story on The Economic Times on 29 Apr 2026
Dr Reddy’s shares slide as Goldman downgrades and Citi goes cautious on pipeline risks

Dr Reddy’s shares slide as Goldman downgrades and Citi goes cautious on pipeline risks

Dr Reddy’s shares dropped about 2% after Goldman Sachs downgraded the stock and Citigroup turned cautious. Brokerages pointed to limited growth visibility, pipeline concerns, and valuation risks, alongside generics pricing pressure. Citi also flagged muted near-term opportunities in semaglutide, prompting analysts to warn that downside risks may persist despite earlier optimism.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026
Dr Reddy’s wins approval for generic oral semaglutide after head to head trial

Dr Reddy’s wins approval for generic oral semaglutide after head to head trial

Dr Reddy’s has received regulatory approval in India to roll out its generic oral semaglutide. The approval follows a head to head comparative study in India that found the formulation non inferior to Novo Nordisk’s Rybelsus. The company says this clinical evidence helped it secure approval under India’s biosimilar regulatory pathway.

Summarised by Beize from a story on The Economic Times on 24 Apr 2026

Never miss a story

App StorePlay Store
Page 1

The full experience is on mobile.

Swipe through stories, personalise your feed, and save articles for later — all on the app.

Download on the App StoreGet it on Google Play